Richard Turkington
A5031840599- Esophageal Cancer Research and Treatment
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Cancer-related Molecular Pathways
- Neuropeptides and Animal Physiology
- Esophageal and GI Pathology
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- COVID-19 and healthcare impacts
- Peptidase Inhibition and Analysis
- Cancer Research and Treatments
- Cancer-related gene regulation
- Radiomics and Machine Learning in Medical Imaging
- RNA modifications and cancer
- Bioinformatics and Genomic Networks
- Legal Systems and Judicial Processes
- Gastrointestinal Tumor Research and Treatment
- Law, Rights, and Freedoms
- Epigenetics and DNA Methylation
- Lung Cancer Diagnosis and Treatment
- Genomics and Phylogenetic Studies
- Evolution and Genetic Dynamics
Queen's University Belfast
2016-2025
Edinburgh Royal Infirmary
2024
NHS Lothian
2024
Almac (United Kingdom)
2024
Belfast Health and Social Care Trust
2017-2023
The Northern Ireland Cancer Centre
2007-2023
Belfast City Hospital
2007-2023
University of Ulster
2007-2023
Laboratoire des Sciences de l'Ingénieur, de l'Informatique et de l'Imagerie
2020-2022
University of Birmingham
2018-2021
The optimum curative approach to adenocarcinoma of the oesophagus and oesophagogastric junction is unknown. We aimed compare trimodality therapy (preoperative radiotherapy with carboplatin plus paclitaxel [CROSS regimen]) contemporaneous perioperative chemotherapy regimens (epirubicin cisplatin or oxaliplatin fluorouracil capecitabine [a modified MAGIC regimen] before 2018 fluorouracil, leucovorin, oxaliplatin, docetaxel [FLOT] subsequently).
The College of American Pathologists (CAP) has developed a guideline on testing for mismatch repair (MMR) and microsatellite instability (MSI) patients considered immune checkpoint inhibitor therapy. ASCO policy set procedures endorsing clinical practice guidelines that have been by other professional organizations.The CAP was reviewed developmental rigor methodologists. An Endorsement Panel subsequently the content recommendations.The determined recommendations from guideline, published...
Abstract CDKN2A is a tumor suppressor located in chromosome 9p21 and frequently lost Barrett’s esophagus (BE) esophageal adenocarcinoma (EAC). How other gene co-deletions affect EAC evolution remains understudied. We explored the effects of loss EACs cancer progressor non-progressor BEs with matched genomic, transcriptomic clinical data. Despite its driver role, BE prevents initiation by counterselecting subsequent TP53 alterations. predict poor patient survival but not through...
Abstract Background This multicentre cohort study sought to define a robust pathological indicator of clinically meaningful response neoadjuvant chemotherapy in oesophageal adenocarcinoma. Methods A questionnaire was distributed 11 UK upper gastrointestinal cancer centres determine the use assessment chemotherapy. Records consecutive patients undergoing oesophagogastric resection at seven between January 2000 and December 2013 were reviewed. Pathological assessed using Mandard Tumour...
The discovery of underlying mechanisms drug resistance, and the development novel agents to target these pathways, is a priority for patients with advanced colorectal cancer (CRC). We previously undertook systems biology approach design functional genomic screen identified fibroblast growth factor receptor 4 (FGFR4) as potential mediator resistance. aim this study was examine role FGFR4 in resistance using RNAi small-molecule inhibitor BGJ398 (Novartis). found that highly expressed at RNA...
PURPOSE There is limited evidence regarding the prognostic effects of pathologic lymph node (LN) regression after neoadjuvant chemotherapy for esophageal adenocarcinoma, and a definition LN response lacking. This study aimed to evaluate how influences survival surgery adenocarcinoma. METHODS Multicenter cohort patients with adenocarcinoma treated followed by surgical resection at five high-volume centers in United Kingdom. LNs retrieved esophagectomy were examined given score (LNRS)—LNRS 1,...
Abstract The activation of apoptosis signalling by TRAIL (TNF-related apoptosis-inducing ligand) through receptor binding is a fundamental mechanism cell death induction and often perturbed in cancer cells to enhance their survival treatment resistance. Ubiquitination plays an important role the regulation TRAIL-mediated apoptosis, here we investigate E3 ubiquitin ligase Itch oesophageal cells. Knockdown expression results resistance TRAIL-induced caspase-8 activation, Bid cleavage also...
Abstract Background Early cancer recurrence after oesophagectomy is a common problem, with an incidence of 20–30 per cent despite the widespread use neoadjuvant treatment. Quantification this risk difficult and existing models perform poorly. This study aimed to develop predictive model for early surgery oesophageal adenocarcinoma using large multinational cohort machine learning approaches. Methods Consecutive patients who underwent had treatment in one Dutch six UK oesophagogastric units...
Abstract Background The restructuring of healthcare systems to cope with the demands COVID-19 pandemic has led a reduction in clinical services such as cancer screening and diagnostics. Methods Data from four Northern Ireland pathology laboratories were used assess trends pathological diagnoses 1st March 12th September 2020 overall by site, sex age. These compared same timeframe 2017 2019. Results Between 2020, there was 23% time period preceding 3 years. Although some recovery occurred...
Abstract Esophageal adenocarcinoma is a prominent example of cancer characterized by frequent amplifications in oncogenes. However, the mechanisms leading to amplicons that involve breakage-fusion-bridge cycles and extrachromosomal DNA are poorly understood. Here, we use 710 esophageal cases with matched samples patient-derived organoids disentangle complex their associated mechanisms. Short-read sequencing identifies ERBB2 , MYC MDM2, HMGA2 as most oncogenes amplified DNAs. We resolve...
TPS512 Background: Oesophagogastric adenocarcinoma (OGA) is globally prevalent and frequently advanced at presentation. Less than 50% of patients with operable OGA are cured when treated multimodality therapy. Patients in the UK OGA, FLOT prior to following surgery. However, who have circulating tumour DNA (ctDNA) their blood after surgery worse survival ctDNA negative patients. Therefore, use novel treatment approaches aiming cure this micrometastatic disease considered a rational...
A major factor limiting the effective clinical management of colorectal cancer (CRC) is resistance to chemotherapy. Therefore, identification novel, therapeutically targetable mediators vital.
// Muhammad A. Alvi 1, * , Darragh G. McArt Paul Kelly 2 Marc-Aurel Fuchs 1 Matthew Alderdice Clare M. McCabe Victoria Bingham Claire McGready Shailesh Tripathi 3 Frank Emmert-Streib Maurice B. Loughrey Stephen McQuaid Perry Maxwell Peter W. Hamilton Richard Turkington 4 Jacqueline James H. Wilson Manuel Salto-Tellez Northern Ireland Molecular Pathology Laboratory, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Ireland, UK Tissue Pathology, Belfast Health Social...
Signet ring cell colorectal cancer (SRCCa) has a bleak prognosis. Employing molecular pathology techniques we investigated the potential of precision medicine in this disease.
The identification of cancer-promoting genetic alterations is challenging particularly in highly unstable and heterogeneous cancers, such as esophageal adenocarcinoma (EAC). Here we describe a machine learning algorithm to identify cancer genes individual patients considering all types damaging simultaneously. Analysing 261 EACs from the OCCAMS Consortium, discover helper that, alongside well-known drivers, promote cancer. We confirm robustness our approach 107 additional EACs. Unlike...
Histone deacetylase inhibitors (HDACi) have emerged as promising therapeutics for the treatment of neurodegeneration, cancer, and rare disorders. Herein, we report development a series spiroindoline-based HDAC6 isoform-selective based on X-ray crystal studies hit 6a. We identified compound 6j most potent selective hHDAC6 inhibitor series. Biological investigation compounds 6b, 6h, demonstrated their antiproliferative activity against several cancer cell lines. Western blotting indicated that...
Abstract A variety of mutational processes drive cancer development, but their dynamics across the entire disease spectrum from pre-cancerous to advanced neoplasia are poorly understood. We explore mutagenic shaping oesophageal adenocarcinoma tumorigenesis in 997 instances comprising distinct stages this malignancy, Barrett Oesophagus primary tumours and metastatic disease. The landscape is dominated by C[T > C/G]T substitution enriched signatures SBS17a/b, which linked with TP53...
Objective Current strategies to guide selection of neoadjuvant therapy in oesophageal adenocarcinoma (OAC) are inadequate. We assessed the ability a DNA damage immune response (DDIR) assay predict following chemotherapy OAC. Design Transcriptional profiling 273 formalin-fixed paraffin-embedded prechemotherapy endoscopic OAC biopsies was performed. All patients were treated with platinum-based and resection between 2003 2014 at four centres Oesophageal Cancer Clinical Molecular Stratification...
Abstract Purpose To investigate the association between cigarette smoking, alcohol consumption, and esophageal adenocarcinoma survival, including stratified analysis by selected prognostic biomarkers. Methods A population-representative sample of 130 patients (n = 130) treated at Northern Ireland Cancer Centre 2004 2012. Cox proportional hazards models were applied to evaluate associations smoking status, intake, survival. Secondary analyses investigated these across categories p53, HER2,...
Abstract Background Limited studies examine the immune landscape in Esophageal Adenocarcinoma (EAC). We aim to identify novel associations, which may inform immunotherapy treatment stratification. Methods Three hundred twenty-nine EAC cases were available Tissue Microarrays (TMA) format. A discovery cohort of 166 stained immunohistochemically for range adaptive (CD3, CD4, CD8 and CD45RO) checkpoint biomarkers (ICOS, IDO-1, PD-L1, PD-1). validation 163 was also accessed. digital pathology...